LOW-DOSE TOPICAL MITOMYCIN-C IN SEVERE VERNAL KERATOCONJUNCTIVITIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ROUZI TALAB M.H.; MANSOURI F.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: BINA Year:2002 | Volume:7 | Issue:4 Page(s): 302-305

Download Full-Text

Persian Verion

View:

955

Download:

Cites:

Information Journal Paper

Title

LOW-DOSE TOPICAL MITOMYCIN-C IN SEVERE VERNAL KERATOCONJUNCTIVITIS

Author(s)

ROUZI TALAB M.H. | MANSOURI F. | Issue Writer Certificate

Keywords

SEVERE VERNAL KERATOCONJUNCTIVITISQ3

MITOMYCIN-CQ3

Abstract

Purpose: To evaluate the efficacy and safety of low-dose topical MITOMYCIN-C in patients with severe vernal keratoconjunctvitis.Materials and methods: In this placebo-controlled randomized clinical trial, patients with severe keratoconjunctivitis were randomly assigned to treatment with topical MITOMYCIN-C 0.01% eye drops (N= 31) or placebo (N= 27), three times daily for 2 weeks. Symptoms including, itching, photophobia, tearing, mucous discharge, foreign body sensation; and signs including conjunctival hyperemia, epithelial conjunctival giant papillae of the patients were recorded on the day of enrollment and at the end of the treatment period.Results: There was a statistically significant decrease in the signs and symptoms in the MITOMYCIN-C treated group at the end of 2 weeks of treatment. One of the treated patients (3.2%) and 26 of the placebo group (96%), required medication during the 4-week post-treatment follow up period.Conclusions: Short term, low-dose topical MITOMYCIN-C may be considered in the acute exacerbations of SEVERE VERNAL KERATOCONJUNCTIVITIS.

Cites

References

No record.

Cite

APA: Copy

ROUZI TALAB, M.H., & MANSOURI, F.. (2002). LOW-DOSE TOPICAL MITOMYCIN-C IN SEVERE VERNAL KERATOCONJUNCTIVITIS. BINA, 7(4), 302-305. SID. https://sid.ir/paper/42351/en

Vancouver: Copy

ROUZI TALAB M.H., MANSOURI F.. LOW-DOSE TOPICAL MITOMYCIN-C IN SEVERE VERNAL KERATOCONJUNCTIVITIS. BINA[Internet]. 2002;7(4):302-305. Available from: https://sid.ir/paper/42351/en

IEEE: Copy

M.H. ROUZI TALAB, and F. MANSOURI, “LOW-DOSE TOPICAL MITOMYCIN-C IN SEVERE VERNAL KERATOCONJUNCTIVITIS,” BINA, vol. 7, no. 4, pp. 302–305, 2002, [Online]. Available: https://sid.ir/paper/42351/en

Related Journal Papers